Tag Archives: Early Diagnosis

Blood Test Able to Predict Alzheimer’s Disease Decades Before Symptoms? (BBC News / Neurology)

Posted on August 3, 2019 by Dementia and Elderly Care News

Summary Research published in the Neurology journal claims a significant breakthrough in the development of a blood test (for plasma Aβ42/Aβ40) which may be able to predict Alzheimer’s Disease onset with 94% accuracy. Due caution: “But it’s important to note … Continue reading →

Posted in BBC News, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Quick Insights, Universal Interest | Tagged Alzheimer's Disease: Diagnosis, Alzheimer’s Early Screening, Amyloid, Amyloid and Tau PET, Amyloid Beta, Amyloid Beta (Aβ42 and Aβ40), Amyloid Beta Protein, Amyloid-β (Aβ), Amyloid-β Protein, BBC Health News, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Blood Proteins as Biomarkers of Disease Research, Blood Test for Brain Amyloidosis: Validated Using Amyloid PET and CSF p-tau181/Aβ42 as Reference Standards, Blood Tests, Blood-Based Biomarkers, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer’s Disease, Brain Imaging, Brain Research, Case Finding, Conversion to Dementia From Prodromal Disease, Dementia Diagnosis, Dementia Innovation, Dementia Research, Dementia Screening, Department of Neurology: Washington University, Diagnosis, Diagnosis of Alzheimer's Disease, Diagnostic Imaging, Division of Biostatistics: Washington University, Drug Development for Alzheimer's Disease, Early Detection of Preclinical Disease, Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Hope Center for Neurological Disorders: Washington University, Knight Alzheimer's Disease Research Center: Washington University, Mallinckrodt Institute of Radiology: Washington University, Neurology (Journal), Non-Invasive Biomarkers, Plasma Biomarkers, Plasma β-Amyloid 42/40, Plasma Protein Markers of MRI Measures in Asymptomatic Individuals, Preclinical Alzheimer's Disease, Preclinical Biomarkers in Alzheimer's Disease, Predictive Ability (of Tests), Prodromal Alzheimer's Disease, Protein-Based Biomarkers in Blood May Deliver Accurate Diagnoses, Rapid Screening, Recruitment Onto Dementia Clinical Trials, SAP (Protein), SAP: Serum Amyloid Protein, Screening, Screening for Dementia, Washington University School of Medicine | Leave a comment

Dementia Biomarkers Re-Explored? (General Psychiatry / JGCR)

Posted on June 17, 2019 by Dementia and Elderly Care News

Summary A recent systematic review examines biomarkers, as strictly defined, for neurodegenerative diseases. “Vast improvements in neuroimaging techniques have led to newly discovered biomarkers and diagnostics”. p.5 Behavioural biomarkers are mentioned hardly at all. Full Text Link Reference Maclin, JMA. … Continue reading →

Posted in Alzheimer’s Research UK, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Mental Health, Personalisation, Quick Insights, Systematic Reviews, UK, Universal Interest | Tagged 18F-florbetaben, 18F-flutemetamol, 18Fflorbetapir, Alzheimer's Disease: Diagnosis, Alzheimer’s Disease, Alzheimer’s Disease and Dementia, Alzheimer’s Disease Biomarkers, Alzheimer’s Research UK (ARUK), Amyloid and Tau PET, APOE e4 (Apolipoprotein E e4), Apolipoprotein E (APOE) e4 Allele, Behavioural Biomarkers, Beta-Amyloid PET Imaging, Biomarker Development, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Canonical Syndromes of Primary Progressive Aphasia: Non-Fluent / Agrammatic Variant (nfvPPA), Canonical Syndromes of Primary Progressive Aphasia: Semantic Variant (svPPA), Carbon-11 Pittsburgh Compound-B (C-PIB) Radioisotope Tracer, Cerebral Metabolic Rate for Glucose (CMRgl), Cerebrospinal Fluid (CSF) Biomarkers, Cerebrospinal Fluid and Serum MHPG, CMRgl Decline, Corticobasal Degeneration (CBD), CSF 3-methoxy-4-hydrox-yphenylglycol (MHPG), Dementia With Lewy Bodies (DLB), Differential Diagnosis, DLB: Dementia with Lewy Bodies, Docosahexaenoic Acid (DHA), Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Eicosapentaenoic Acid (EPA), Frontotemporal Dementia (FTD), α-Synuclein, Journal of Geriatric Care and Research (JGCR), Lewy Body Dementia (LBD), Magnetic Resonance Imaging (MRI), Medial Temporal Lobe Atrophy (MTA), Medial Temporal Lobes (MTL), Metabolic Syndrome (MetS), MRI Brain Imaging, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neuroimaging, Neuroimaging in Dementia Diagnosis, Non-Invasive Biomarkers, Pick’s Disease (Frontotemporal Dementia), Positron Emission Tomography (PET), Preclinical Alzheimer's Disease, Primary Progressive Aphasia (PPA), Progressive Supranuclear Palsy (PSP), Rapid Screening, Screening for Dementia, Sea Hero Quest (SHQ) Game, Sea Hero Quest VR, Tau PET, Timely Diagnosis, VaD: Vascular Dementia, Variants of Primary Progressive Aphasia (PPA), Vascular Dementia, [18F]THK5351 | Leave a comment

Smell Test for Early Detection of Parkinson’s Disease (BBC News)

Posted on March 21, 2019 by Dementia and Elderly Care News

Summary Parkinson’s Disease has a distinctive odour for certain gifted individuals, which has been analysed chemically and may now be replicated for automated detection by machine. This may, in future, permit earlier diagnosis and open the possibilities for timely treatments … Continue reading →

Posted in BBC News, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Parkinson's Disease, Quick Insights, Scotland, UK, Universal Interest | Tagged ACS Central Science (Journal), Anatune (Cambridge UK), BBC Health News, BBC Scotland News, Biomarkers, Biomarkers Predicting Parkinson's Disease, Department of Biochemistry: University of Liverpool, Department of Neurology: Salford Royal Foundation Trust, Early Diagnosis, Early Diagnosis of Parkinson’s Disease, Edinburgh University, Eicosane, Hyperosmic Super Smeller, Institute for Stem Cell Research: University of Edinburgh, Institute of Integrative Biology: University of Liverpool, Joy Milne, Les Milne, Manchester Academic Health Science Centre: University of Manchester, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Non-Invasive Biomarkers, Odour, Parkinson's Disease Smell Test, Parkinson’s Disease Sebum Volatilome, Parkinson’s UK, Perillic Aldehyde, Rapid Screening, Salford Royal Foundation Trust, School of Biological Sciences: University of Edinburgh, Sebum, Smell Test for Parkinson's Disease Diagnosis, Timely / Preclinical Parkinson's Disease Diagnosis, Timely Diagnosis, University of Edinburgh, University of Liverpool, University of Manchester, Volatile Biomarkers of Parkinson’s Disease, Volatilome | Leave a comment

Eye Tests for Early Detection of Alzheimer’s Disease? (NHS Digital / Ophthalmology Retina)

Posted on March 20, 2019 by Dementia and Elderly Care News

Summary Further discussion about the possibilities of using inexpensive eye tests to detect Alzheimer’s Disease, perhaps years before symptoms appear. This particular technique involves the examination of blood vessels and blood flow in the retina, as detected by Octa (Optical … Continue reading →

Posted in Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, NHS Digital (Previously NHS Choices), Quick Insights, Universal Interest | Tagged Alzheimer's Disease: Diagnosis, Alzheimer’s Disease, Alzheimer’s Disease and Dementia, Alzheimer’s Disease Biomarkers, Assessment and Diagnosis, Bazian, Behind the Headlines, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Central Subfield Thickness (CST), Cognitive Impairment, Critical Appraisals, Dementia Case Finding, Dementia Diagnosis, Dementia Screening, Diagnosis, Diagnosis of Alzheimer's Disease, Diagnostics, Duke University in North Carolina, Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Early Treatment Diabetic Retinopathy Study, Eye Examinations, Foveal Avascular Zone (FAZ) Area, Karen L. Wrenn Alzheimer's Disease Award, Macular Ganglion Cell-Inner Plexiform Layer (GC-IPL), MCI: Mild Cognitive Impairment, Mild Cognitive Impairment, National Institutes of Health, National Institutes of Health (NIH), National Institutes of Health (US), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, NHS Digital (Formerly NHS Choices), Non-Invasive Biomarkers, Octa: Optical Coherence Tomography Angiography, Ophthalmology Retina, Optical Coherence Tomography, Optical Coherence Tomography Angiography (OCTA), Preclinical Alzheimer's Disease, Rapid Screening, Research to Prevent Blindness Inc. (New York), Retina as Early Biomarker of Neurodegeneration, Retinal Biomarkers, Retinal Examination in Neurodegenerative Diseases, Retinal Microvascular and Neurodegenerative Changes in Alzheimer’s Disease, Retinal Microvascular and Neurodegenerative Changes in Mild Cognitive Impairment, Retinal Vessel Density (VD), Screening, Screening for Dementia, Timely Diagnosis, US National Institutes of Health (NIH), USA | Leave a comment

Latest Dementia Assessment and Referral Data for 2018 (NHS England)

Posted on February 14, 2019 by Dementia and Elderly Care News

Summary NHS England has published dementia assessment and referral statistics, as of November 2018. These statistics aim to monitor and improve (i) the identification of older patients with dementia and delirium, (ii) assessment and appropriate referral and (iii) follow-up after people have been … Continue reading →

Posted in Acute Hospitals, Commissioning, Community Care, Delirium, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), Integrated Care, Local Interest, Management of Condition, Mental Health, Models of Dementia Care, National, NHS, NHS England, Patient Care Pathway, Person-Centred Care, Quick Insights, Standards, Statistics, UK, Universal Interest | Tagged Acute Care, Acute Hospitals, Acute Trusts, Acute Trusts: Find and Assess/Investigate Measures, Assessment, Assessment and Referral, Case Finding, Case Finding for Patients with Dementia, Checks for Dementia at Age 75 Years, Clinical Commissioning Group (CCG): Refer/Inform Measures, Clinical Commissioning Groups (CCGs), Community and Mental Health Trusts, Community Service Providers, Community Service Providers (Community and Mental Health Trusts), Community Services, Community Services Providers, Dementia Assessment and Referral 2015-16, Dementia Assessment and Referral Data, Dementia Assessment and Referral Data Collection, Dementia Assessment and Referral Statistics, Dementia Care in Acute General Hospital, Dementia Care in Acute Settings, Dementia Care in Emergency Departments, Dementia Care in General Hospitals, Dementia Case Finding, Dementia Case Finding Scheme, Dementia Commissioning for Quality and Innovation (CQUIN), Dementia CQUIN, Dementia CQUIN: FAIR (Find; Assess and Investigate; Refer), Dementia Diagnostic Assessment, Dementia Friendly Acute Hospitals, Dementia Liaison Services, Dementia Statistics, Diagnosis and Referral, Discharge Planning, Early Diagnosis, FAIR (Find; Assess and Investigate; Refer), FAIRI: Find Assess/Investigate Refer/Inform, FAR: Find Assess Refer, General Hospitals, General Practice, General Practice Performance Data, Identification and Referral, Incentive Payments, Liaison Mental Health Services, Liaison Psychiatry Services, Liaison Services, Mental Health and Community Services, National Commissioning for Quality and Innovation (CQUIN) Payment Framework, National Commissioning for Quality and Innovation “CQUIN” Payment Framework (Department of Health), National Dementia CQUIN, Performance Incentives, Referral and Assessment, Referrals, Timely Diagnosis | Leave a comment

More on Possible Blood Tests for Pre-Symptomatic Alzheimer’s Disease (NHS Digital / Nature Medicine)

Posted on January 28, 2019 by Dementia and Elderly Care News

Summary People with a rare hereditary form of Alzheimer’s Disease (Dominantly Inherited Alzheimer’s Disease) have raised levels of a protein called neurofilament light chain (NfC) in their blood, arising from damage to previously healthy nerve cells. These elevated levels of … Continue reading →

Posted in Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, NHS Digital (Previously NHS Choices), Quick Insights, Universal Interest | Tagged APP or PSEN Mutations, Australia, Basel, Bazian, Behind the Headlines, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Blood Proteins as Biomarkers of Disease Research, Blood-Based Biomarkers, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer’s Disease, Columbia University Medical Center, Dementia Research Centre, Dementia Research Centre: University College London, Department of Biomedical Sciences: Macquarie University, Department of Cellular Neurology: Hertie Institute for Clinical Brain Research, Department of Neurodegeneration: Queen Square Institute of Neurology, Department of Neurology: Columbia University Medical Center, Department of Neurology: Keck School of Medicine at USC, Department of Neurology: Ludwig-Maximilians-Universität München, Department of Neurology: Massachusetts General Hospital, Department of Neurology: Mayo Clinic Jacksonville, Department of Neurology: Washington University School of Medicine, Department of Neuroscience: Icahn School of Medicine at Mount Sinai, Department of Psychiatry and Psychotherapy: University of Tübingen, Department of Radiology: Washington University School of Medicine, Departments of Medicine Biomedicine and Clinical Research: University Hospital Basel, Division of Biostatistics: Washington University School of Medicine, Dominantly Inherited Alzheimer Network, Dominantly Inherited Alzheimer Network (DIAN), Dominantly Inherited Alzheimer's Disease, Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Edith Cowan University: Western Australia, Florey Institute of Neuroscience and Mental Health: University of Melbourne, German Center for Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE), Germany, Harvard Medical School, Hereditary Alzheimer's Disease, Hertie Institute for Clinical Brain Research, Icahn School of Medicine at Mount Sinai (New York), Indiana Alzheimer Disease Center and Department of Pathology and Laboratory Medicine: Indiana University School of Medicine, Indiana University School of Medicine, Ludwig-Maximilians-Universität München, Macquarie University, Macquarie University (New South Wales), Massachusetts General Hospital, National Institute on Aging, National Institute on Aging (NIA), National Institute on Aging (US), Nature Medicine, Neurodegeneration Division: The Florey Institute of Neuroscience and Mental Health, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurofilament Light Chain (NfC), Neurofilament Light Chain (NFL), Neurofilament Light Protein (NF-L), Neurofilament Light Protein in Blood: Potential Biomarker of Neurodegeneration, Neurologic Clinic and Policlinic: University Hospital Basel, Neuroscience Research Australia, Non-Invasive Biomarkers, Plasma Biomarkers, Preclinical Alzheimer's Disease, Preclinical Biomarkers and Dementia, Preclinical Biomarkers in Alzheimer's Disease, Protein-Based Biomarkers in Blood May Deliver Accurate Diagnoses, School of Medical Health and Sciences: Edith Cowan University, School of Medical Sciences: University of New South Wales, Serum Neurofilament Light Chain Protein, Switzerland, Taub Institute for Research on Alzheimer's Disease and the Aging Brain: Columbia University Medical Center, United States, University College London, University Hospital Basel, University of Basel, University of Melbourne, University of New South Wales, University of Tübingen, US National Institute on Aging, USA, Warren Alpert Medical School of Brown University, Washington University School of Medicine | Leave a comment

Signs of Dementia or Depression Often First Detected at Christmas? NHS England)

Posted on December 25, 2018 by Dementia and Elderly Care News

Summary Professor Alistair Burns, NHS England’s National Clinical Director for Dementia and Older Peoples’ Mental Health, has again written briefly about the role of family and friends in identifying early signs of dementia or depression when meeting older people / … Continue reading →

Posted in Community Care, Depression, Diagnosis, For Carers (mostly), For Nurses and Therapists (mostly), National, NHS England, Patient Information, Quick Insights, UK, Universal Interest | Tagged Advice and Information, Advice and Support, Alistair Burns: NHS England’s National Clinical Director for Dementia, Alistair Burns: NHS England’s National Clinical Director for Older People’s Mental Health, Awareness Raising, Barbara Windsor, BBC Health News, Check Your Mate: NHS England’s Valentine’s Day Advice, Community Involvement, Community Participation, Dame Barbara Windsor, Dementia and Age-Friendly Neighbourhoods, Dementia Awareness, Dementia Awareness Campaign, Dementia Friendly Christmas, Dementia Friends, Dementia Friends Campaign, Dementia Friends Programme, Disorientation, Early Diagnosis, Family Involvement, Family Meetings, Festive Season, Identification and Referral, Information and Advice, Mental Wellbeing and Older People, Professor Alistair Burns, Reducing Delays in Dementia Diagnosis, Scott Mitchell, Social Networks, Spatial Disorientation, Spotting the Signs of Dementia, Supportive Social Networks, Timely Diagnosis, Valentine’s Day | Leave a comment

Tag Archives: Early Diagnosis

Blood Test Able to Predict Alzheimer’s Disease Decades Before Symptoms? (BBC News / Neurology)

Dementia Biomarkers Re-Explored? (General Psychiatry / JGCR)

Smell Test for Early Detection of Parkinson’s Disease (BBC News)

Eye Tests for Early Detection of Alzheimer’s Disease? (NHS Digital / Ophthalmology Retina)

Latest Dementia Assessment and Referral Data for 2018 (NHS England)

More on Possible Blood Tests for Pre-Symptomatic Alzheimer’s Disease (NHS Digital / Nature Medicine)

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites